{"entity":{"id":"akoya-biosciences","kind":"company","name":"Akoya Biosciences (Quanterix)","aka":[],"tldr":"Spatial proteomics (PhenoCycler, PhenoImager) used to map immune cells in tumours; acquired by Quanterix in July 2025.","summary":"Akoya Biosciences, based in Marlborough, Massachusetts, and formerly listed as AKYA, makes spatial proteomics instruments, PhenoCycler and PhenoImager, used to map immune cells in tumours, and it became a wholly owned subsidiary of Quanterix on 8 July 2025. Its multiplex immunofluorescence runs at scale, and clinical partnerships aim at spatial signatures that predict immunotherapy response. OnCo links it to spatial biology instruments. Whether a spatial immune signature can be validated as a companion diagnostic for immunotherapy, which is the promise behind the whole sector, is the open question. The spatial biology instruments page carries the wider field.","asOf":"2026-10-29","links":[{"label":"Official website (now Quanterix)","url":"https://www.quanterix.com"},{"label":"Quanterix quarterly report recording the Akoya acquisition (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1503274/000150327425000106/qtrx-20250930.htm"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["spatial-biology-instruments"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Checked 29 October 2026 against Quanterix's quarterly report for the period ended 30 September 2025 (SEC), which states the Akoya Closing Date as 8 July 2025 and Akoya surviving as a wholly owned subsidiary. akoyabio.com now redirects to quanterix.com, where the PhenoCycler and PhenoImager instruments are sold under the Akoya name, so the website field points to the acquirer."],"hq":"Marlborough, MA","country":"US","companyType":"diagnostics","website":"https://www.quanterix.com","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"amountUsd":150973000,"source":"https://www.sec.gov/Archives/edgar/data/1503274/000150327425000106/qtrx-20250930.htm","note":"Closed 8 July 2025 under an amended merger agreement; Quanterix's 10-Q gives a total fair value of consideration of 151.0 million dollars, including Quanterix shares, about 18.9 million dollars in cash and repayment of Akoya's debt"}]},"route":"/companies/akoya-biosciences/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"spatial-biology-instruments","kind":"technology","name":"Spatial biology instruments","route":"/technologies/spatial-biology-instruments/"}]}}